Michael Glen Kauffman's Insider Trades & SAST Disclosures
Michael Glen Kauffman's most recent trade in Adicet Bio Inc was a trade of 37,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 21, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Glen Kauffman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 37,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 8,333 | 8,883 (0%) | 0% | 0 | Common Stock | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,900 | 11,800 | - | 0 | Common Stock | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 1.43 per share. | 05 Jun 2024 | 5,900 | 5,900 | - | 1.4 | 8,437 | Common Stock |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 16,078 | 16,078 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 1,497 | 0 | - | - | Stock Option (right to buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 37,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,900 | 5,900 | - | 0 | Common Stock | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 21,000 | 719,983 (1%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 28 Feb 2022 | 6,226 | 898,131 (1%) | 0% | 10.2 | 63,739 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 28 Feb 2022 | 6,226 | 713,757 (1%) | 0% | 10.2 | 63,739 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 12.12 per share. | 17 Feb 2022 | 9,088 | 904,357 (1%) | 0% | 12.1 | 110,177 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 12.12 per share. | 17 Feb 2022 | 9,079 | 698,983 (1%) | 0% | 12.1 | 110,068 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 6,764 | 708,062 (1%) | 0% | 9.9 | 66,707 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 6,707 | 913,445 (1%) | 0% | 9.9 | 66,144 | Common Stock |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 03 Jan 2022 | 5,000 | 63,690 (0%) | 0% | 16.5 | 82,250 | Common Stock |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 5,000 | 3,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.91 per share. | 03 Jan 2022 | 5,000 | 68,690 (0%) | 0% | 5.9 | 29,550 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges